Introduction
============

Hypoxemia is a hallmark of several disease states including obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), and acute mountain sickness and is also experienced during recreational activities (e.g., diving, hiking). In these conditions, maintaining (or restoring) oxygen delivery to skeletal muscle, cardiac muscle, and the brain is fundamentally important or impaired performance and eventual tissue necrosis may ensue. Human experiments have shown that hypoxemia raises ventilation, heart rate, and muscle sympathetic nerve activity (Saito et al. [@b54]; Rowell et al. [@b53]; Somers et al. [@b58]). An increase in muscle sympathetic nerve activity helps to redistribute blood flow to vital organs. Despite this acute rise in vasoconstrictor nerve traffic to the resting limb, a net vasodilation occurs in both skeletal muscle and the skin in young healthy subjects (Heistad and Wheeler [@b18]; Kravec et al. [@b29]; Leuenberger et al. [@b32]; Moradkhan et al. [@b40]; Simmons et al. [@b56]). The net vascular effects are referred to as "hypoxia‐induced vasodilation" and this process is important to enhance oxygen delivery to tissues. Previous studies have demonstrated a 20--35% increase in forearm blood flow (FBF) (Leuenberger et al. [@b33]; Weisbrod et al. [@b63]), a 25--35% increase in femoral blood flow (Leuenberger et al. [@b34]; DeLorey et al. [@b9]) and a 15--30% increase in forearm cutaneous vascular conductance (CVC) (Simmons et al. [@b56]) in healthy people age 18--33. However, the influence of healthy aging on hypoxia‐induced vasodilation (both muscle blood flow and skin blood flow) is largely unknown.

Older adults (age 50--75) experience a blunted tachycardia in response to hypoxia compared to young subjects (Kronenberg and Drage [@b30]; Lhuissier et al. [@b35]) whereas differences in ventilation (Lhuissier et al. [@b35]; Muller et al. [@b44]), blood pressure (BP), and muscle sympathetic nerve activity (MSNA) are not consistently observed. Indeed, Davy et al. ([@b8]) demonstrated that the increases in MSNA and BP were comparable between young (24 ± 1 years) and older subjects (age 64 ± 1 years). When considering the vascular responses to hypoxia, two studies have demonstrated age‐related impairments in forearm blood flow (Kravec et al. [@b29]; Kirby et al. [@b27]) but two other studies did not observe differences between groups (Casey et al. [@b5]; Limberg et al. [@b36]). Importantly, none of these studies specifically evaluated skin blood flow responses to hypoxia. Thus, further work in this area is warranted.

The magnitude of hypoxia‐induced vasodilation is partly dependent on endothelial function as well as other local and systemic factors including activation of beta‐ adrenergic receptors (Richardson et al. [@b52]; Richards et al. [@b51]), adenosine (Carlsson et al. [@b3]; Leuenberger et al. [@b33]), prostaglandins (Carlsson et al. [@b3]; Engelke et al. [@b10]), release of ATP from red blood cells (Kirby et al. [@b27]), and local myogenic factors (Carlsson et al. [@b3]; Schubert and Mulvany [@b55]; Koller and Bagi [@b28]). Because endothelial function clearly declines with age (Celermajer et al. [@b7]; Eskurza et al. [@b11]; Newcomer et al. [@b49]; Holowatz et al. [@b21]), it is possible that hypoxia‐induced vasodilation would also be attenuated in older adults. One established concept is that aging is associated with increased levels of oxidative stress, which inactivates endothelial nitric oxide (Gryglewski et al. [@b14]; Katusic and Vanhoutte [@b23]) thereby causing impairments in endothelium‐dependent vasodilation (Taddei et al. [@b60]). Previous human studies have demonstrated that impairments in vascular function due to the aging process can be acutely modified by infusion of high dose ascorbic acid (i.e., a powerful antioxidant capable of scavenging oxygen‐derived free radicals) (Frei [@b12]; Eskurza et al. [@b11]; Monahan et al. [@b39]; Kirby et al. [@b26]). In other words, acute infusion of an antioxidant can enhance vascular function in groups of subjects with enhanced oxidative stress (e.g., older adults). However, it remains to be tested whether oxidative stress influences the acute physiological responses to hypoxia and whether there are differences between skin and muscle blood flow.

With this background in mind, the purpose of the current study was to determine if hypoxia‐induced forearm vasodilation is impaired in older men compared to young men (Experiment 1) and to determine if acute systemic infusion of ascorbic acid would enhance hypoxia‐induced vasodilation in older men (Experiment 2). We hypothesized that older men would display a decreased forearm vasodilator response (Doppler ultrasound and laser Doppler flowmetry) to 5 min of hypoxia compared to young healthy men (Experiment 1) and that ascorbic acid would enhance hypoxia‐induced vasodilation in the older men (Experiment 2).

Methods
=======

Experimental design and subjects
--------------------------------

Experiment 1 used a repeated measures design, between‐subjects design where physiological responses to hypoxia (base, 1, 2, 3, 4, 5 min) were compared between young and older subjects. Experiment 2 used a two treatment (saline, ascorbic acid), repeated measures design and enrolled both young and older men.

All study protocols were approved in advance by the Institutional Review Board of the Penn State Milton S. Hershey Medical Center and conformed to the Declaration of Helsinki. A total of seven young (26 ± 1 years, range 23--29 years) and eight older men (63 ± 1 years, range 55--81 years) participated in Experiment 1 and provided written informed consent. In a similar way, five young men and eight older men participated in Experiment 2 (demographics in [Table 1](#tbl01){ref-type="table"}). Two young men and three older men participated in both Experiments 1 and 2; control trials were repeated in these subjects. Women were excluded due to established differences in vascular responses to chemoreflex activation (Casey et al. [@b6]; Patel et al. [@b50]). All participants had supine resting BP below 130/80 mmHg and all were nonasthmatic, nonobese, nonsmokers, not taking any prescription or vasoactive medication, and were in good health as determined by history and physical examination. All participants reported being physically active but none were competitive athletes. Participants refrained from caffeine, alcohol, and exercise for 24 h before the study. All trials were conducted in the morning, following an overnight fast. Some of the subjects reported to be taking multivitamins but none were consumed on the morning of the study.

###### 

Anthropometric and baseline hemodynamic characteristics.

                          Young         Older
  ----------------------- ------------- --------------------------------------------
  Age (years)             28 ± 1        63 ± 3[\*](#tf1-1){ref-type="table-fn"}
  Height (m)              1.81 ± 0.02   1.79 ± 0.01
  Weight (kg)             81.8 ± 3.5    86.7 ± 3.0
  BMI (kg/m2)             24.9 ± 0.7    26.9 ± 0.7
  SBP (mmHg)              105 ± 4       114 ± 3
  DBP (mmHg)              52 ± 2        75 ± 3[\*](#tf1-1){ref-type="table-fn"}
  MAP (mmHg)              69 ± 1        87 ± 2[\*](#tf1-1){ref-type="table-fn"}
  HR (beats/min)          56 ± 4        57 ± 4
  Triglycerides (mg/dL)   67 ± 3        70 ± 9
  Cholesterol (mg/dL)     132 ± 13      159 ± 8
  HDL (mg/dL)             48 ± 8        44 ± 4
  LDL (mg/dL)             70 ± 6        102 ± 8[\*](#tf1-1){ref-type="table-fn"}
  hs‐CRP (mg/dL)          0.3 ± 0.1     1.6 ± 0.4[\*](#tf1-1){ref-type="table-fn"}
  Fibrinogen (mg/dL)      207 ± 8       286 ± 8[\*](#tf1-1){ref-type="table-fn"}
  Ascorbic acid (mg/dL)   0.8 ± 0.2     0.9 ± 0.1

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; hs‐CRP, high sensitive C‐reactive protein.

Denotes a significant difference from young men. M ± SEM.

Physiological measurements
--------------------------

All experiments were performed in the supine posture in a dimly lit thermoneutral laboratory (22--25°C). Upon arrival to the laboratory, participants dressed in a high‐density tube‐lined suit (Med‐Eng Systems, Ottawa, ON, Canada) that covered the entire body except for the feet, hands, head, and both forearms. Neutral water (34--35°C) was perfused through the suit to maintain mean skin temperature at a constant level and ensure the obtained responses were reflex mediated and not influenced by ambient temperature. After 15 min of quiet rest, baseline BP was obtained via automated oscillometry of the brachial artery (Philips SureSigns Vs3) in triplicate.

Beat‐by‐beat BP was measured by photoplethysmography (Finometer, FMS) and HR was measured via 3‐lead EKG (Cardiocap/5, GE Healthcare). Minute ventilation (MV, L/min) and end tidal CO2 (EtCO2, mmHg) were determined with a respiratory gas monitor (model RGM 5250, Ohmeda) at the expiratory port of a tight‐sealing breathing mask and SaO2 (%) was measured by ear oximetry. Cutaneous blood flow flux was measured by three laser Doppler probes (Moor Instruments, Wilmington, DE) placed on the right ventral forearm with the local temperature set at 34°C.

Beat‐by‐beat mean brachial blood flow velocity was measured in the left arm by Doppler ultrasound (Vivid 7, GE) as previously described (Wilson et al. [@b65]; Muller et al. [@b43]). Briefly, a 9L linear transducer was placed over the left brachial artery and the insonation angle was \<60°. Mean velocity was acquired in pulsed Doppler mode and velocity waveforms were synchronized to a data acquisition system (PowerLab, ADInstruments) by a Doppler audio transformer (Herr et al. [@b19]). Because our ultrasound does not allow for the simultaneous measurement of velocity and diameter, diameter measurements were made during hypoxia and normoxia at the following time points: 60--75, 150--165, and 270--285 s. Thus, we assumed that diameters were the same during minute 1 and 2 and also during minute 3 and 4.

### Experiment 1: Continuous hypoxia in young men versus older men

For the hypoxia trials (10% oxygen), subjects were outfitted with an oronasal facemask for the measurement of MV and EtCO2. Baseline physiological values were obtained for \~3 min and the subjects were then switched to 10% oxygen for five additional minutes, consistent with previous studies (Leuenberger et al. [@b34]; Moradkhan et al. [@b41]; Muller et al. [@b44]). The subjects were not told when the inspiratory gas concentration would be changed.

### Experiment 2: Continuous hypoxia: saline versus ascorbic acid

Based on the findings of Experiment 1, additional studies were conducted in eight older men and five young men. After dressing in the thermal suit, two intravenous catheters were placed. Following 15 min of quiet rest, baseline hemodynamic measurements were obtained. Venous blood was drawn for the measurement of cholesterol, triglycerides, high‐sensitive C‐reactive protein, and fibrinogen. These values were all determined by the Hershey Medical Center Clinical Laboratories following standard laboratory procedures. Serum ascorbic acid was measured by Quest Diagnostic Nichols Institute (San Juan Capistrano, CA). As depicted in [Figure 1](#fig01){ref-type="fig"}, saline infusion always occurred first because high dose ascorbic acid remains in the body for several hours. This experimental approach is consistent with previous reports from our laboratory (Muller et al. [@b43]).

![Timeline for Experiment 2. NSS = normal saline solution, Vit C = ascorbic acid, base = baseline, the arrows denote that a venous blood sample was obtained.](phy2-2-e12091-g1){#fig01}

The dose of ascorbic acid was given based on the participant\'s body weight. A loading dose (45 mg/kg in 100 mL saline) was infused over 20 min followed by a maintenance dose (15 mg/kg in 33 mL saline) for the remainder of the study. The dose was chosen based on past human experiments in which acute intravenous ascorbic acid evoked an antioxidant physiologic effect (Eskurza et al. [@b11]; Monahan et al. [@b39]; Muller et al. [@b42]). Blood samples were drawn from the opposite arm of the infusion. A 10 min break occurred between infusions.

For both normoxia (21%) and hypoxia trials (10% oxygen), subjects were outfitted with an oronasal facemask for the measurement of MV and EtCO2. Baseline physiological values were obtained for \~3 min and the subjects were then switched to either 21% or 10% oxygen for five additional minutes. The subjects were not told what gas they were breathing but the researchers always administered hypoxia second since hypoxia can have long‐lasting effects (Xie et al. [@b68]). Both hypoxia and MVEEA trials were conducted under both saline and ascorbic acid.

Data collection and statistical analysis
----------------------------------------

Data were collected at 200 Hz by a PowerLab (ADInstruments) and were analyzed offline, using the last 15 s of each stage. Forearm blood flow (FBF) was calculated by multiplying the cross‐sectional area (πr^2^) of the vessel by mean brachial blood flow velocity and by 60 to express FBF in units of mL/min. Forearm vascular conductance (FVC) was calculated as FBF/MAP and expressed as a percent change from baseline \[(minute 5‐ baseline)/baseline × 100)\], consistent with prior reports (Muller et al. [@b43]). The three forearm skin blood flow sites were averaged and CVC was calculated as skin blood flow flux/MAP and then expressed as a percent change from baseline which is a common method of data presentation for CVC (Tew et al. [@b62]; Muller et al. [@b45],[@b46]). Changes in HR and MAP from baseline were determined in absolute physiological units.

All statistical analyses were conducted using IBM SPSS 21.0, and graphics were produced using Microsoft Excel and Adobe Illustrator CS5. Baseline anthropometric and hemodynamic parameters were determined with independent samples t‐tests ([Table 1](#tbl01){ref-type="table"}).

For Experiment 1, two group (young, older) by six time point (base, 1, 2, 3, 4, 5 min) repeated measures ANOVAs were conducted to determine the effect of age on physiological responses to hypoxia. For Experiment 2, the effects of normoxia and hypoxia were determined separately with respect to age, infusion, and time by using repeated measures ANOVA. Paired t‐tests were used when a significant group x time interaction was attained. Significance was set at *P* \< 0.05 and data are presented as M ± SEM throughout.

Results
=======

Experiment 1: Continuous hypoxia in young men versus older men
--------------------------------------------------------------

In response to 5 min of breathing 10% oxygen, the young and older men had similar SaO2 (81 ± 2 vs. 81 ± 2%, *P* = 0.891). As shown in [Figure 2](#fig02){ref-type="fig"} (left panel), the older subjects had an attenuated tachycardic response compared to the young subjects. MAP was unchanged by 5 min of hypoxia but was higher in the older men at all time points. At baseline, FVC (*P* = 0.153) and FBF (young: 34 ± 4, older: 31 ± 4 mL/min, *P* = 0.627) were similar between groups. However, the older adults had a significantly attenuated increase in FVC in response to 5 min of hypoxia (i.e., hypoxic vasodilation in skeletal muscle was blunted). Indeed, the percent change in FBF (young: 30 ± 7, older: 13 ± 4%, *P* = 0.036) and FVC (young: 30 ± 7, older: 16 ± 4%, *P* = 0.047) were attenuated in the older adults. However, skin blood flow responses were comparable between groups (young: 35 ± 9, older: 30 ± 6%, *P* = 0.636, [Figure 2](#fig02){ref-type="fig"}).

![Physiologic response to continuous hypoxia. In Experiment 1, heart rate (HR), mean arterial pressure (MAP), forearm vascular conductance (FVC), and forearm cutaneous vascular conductance (CVC) were measured in response to 5 min of continuous hypoxia (10% oxygen) in young men (black diamonds) and older men (white squares). In Experiment 2, older men breathed continuous hypoxia after receiving normal saline solution (NSS, white squares) and ascorbic acid (Vit C, black squares). Data are M ± SEM, \**P* \< 0.05 between groups at each specific time point.](phy2-2-e12091-g2){#fig02}

Experiment 2: Continuous hypoxia: saline versus ascorbic acid
-------------------------------------------------------------

The groups had similar serum levels of ascorbic acid at baseline ([Table 1](#tbl01){ref-type="table"}). The young men received a total of 4908 ± 132 mg of intravenous ascorbic acid during the study and the older men received a total of 4942 ± 85 mg. Infusion of saline had no effect on serum ascorbic acid levels (young: 0.8 ± 0.2 mg/dL, older: 1.0 ± 0.1 mg/dL, *P* = 0.258). After the loading dose of ascorbic acid, serum levels of ascorbic acid drawn from the opposite arm were 15.2 ± 0.6 mg/dL in the young men and 13.6 ± 1.3 mg/dL in the older men (*P* = 0.336 between groups). At the end of the study, serum ascorbic acid was 11.4 ± 0.5 mg/dL in the young men and 11.4 ± 0.7 mg/dL in the older men (*P* = 0.982 between groups). Expectedly, intravenous infusion of ascorbic acid resulted in a 10 to 20‐fold increase in serum levels of ascorbic acid.

Despite the high antioxidant load, the eight older men who received both saline and ascorbic acid had very similar physiological responses to 5 min of breathing 10% oxygen under both infusions. As expected, HR and MV increased in response to 5 min of breathing 10% oxygen under both infusions, whereas SaO2 decreased and EtCO2 also decreased ([Table 2](#tbl02){ref-type="table"}). However, as shown in [Figure 2](#fig02){ref-type="fig"} (right panel), there was no treatment by time interactions for any of the cardiovascular variables. Thus, intravenous ascorbic acid did not alter the physiological response to continuous hypoxia in older men. There was also no effect of ascorbic acid in the young men ([Table 2](#tbl02){ref-type="table"}). Consistent with Experiment 1, there was a blunted tachycardia and blunted forearm vasodilation when comparing the five younger men to the eight older men under both treatments.

###### 

Physiological responses to continuous hypoxia (10% oxygen, 90% nitrogen) in Experiment 2.

                 Base        1 min        2 min        3 min        4 min        5 min        Infuse   Time      Age
  -------------- ----------- ------------ ------------ ------------ ------------ ------------ -------- --------- -------
  HR (bpm)                                                                                                       
  Young NSS      55 ± 3      62 ± 6       66 ± 5       71 ± 5       75 ± 3       80 ± 5       0.001    \<0.001   0.048
  Older NSS      55 ± 3      58 ± 3       59 ± 3       61 ± 3       63 ± 3       64 ± 3                          
  Young Vit C    58 ± 3      67 ± 3       74 ± 2       80 ± 4       80 ± 3       82 ± 5                          
  Older Vit C    57 ± 3      60 ± 3       63 ± 3       64 ± 3       68 ± 4       68 ± 3                          
  MAP (mmHg)                                                                                                     
  Young NSS      79 ± 7      81 ± 8       80 ± 8       76 ± 9       77 ± 8       78 ± 7       0.877    0.402     0.045
  Older NSS      92 ± 4      94 ± 4       91 ± 4       91 ± 4       91 ± 5       92 ± 5                          
  Young Vit C    78 ± 6      77 ± 7       78 ± 6       78 ± 6       77 ± 6       75 ± 6                          
  Older Vit C    92 ± 2      95 ± 3       96 ± 4       93 ± 4       94 ± 4       94 ± 4                          
  FBF (mL/min)                                                                                                   
  Young NSS      33 ± 5      39 ± 6       44 ± 8       44 ± 8       44 ± 8       41 ± 7       0.956    0.014     0.008
  Older NSS      22 ± 4      21 ± 4       18 ± 3       21 ± 4       21 ± 3       25 ± 4                          
  Young Vit C    33 ± 4      35 ± 5       38 ± 5       38 ± 6       40 ± 4       44 ± 7                          
  Older Vit C    24 ± 3      23 ± 2       24 ± 3       23 ± 4       25 ± 4       25 ± 3                          
  CVC (au)                                                                                                       
  Young NSS      100 ± 0     107 ± 5      118 ± 3      150 ± 10     147 ± 6      143 ± 6      0.253    \<0.001   0.068
  Older NSS      100 ± 0     96 ± 4       104 ± 6      117 ± 9      117 ± 9      122 ± 6                         
  Young Vit C    100 ± 0     97 ± 5       114 ± 10     125 ± 12     136 ± 11     147 ± 10                        
  Older Vit C    100 ± 0     95 ± 3       99 ± 7       116 ± 6      118 ± 9      120 ± 7                         
  SaO2 (%)                                                                                                       
  Young NSS      97 ± 0.5    92 ± 0.9     88 ± 0.6     84 ± 0.9     83 ± 1.8     82 ± 2.4     0.291    \<0.001   0.218
  Older NSS      97 ± 0.3    93 ± 0.9     90 ± 1.0     88 ± 1.3     84 ± 1.5     83 ± 1.6                        
  Young Vit C    98 ± 0.3    82 ± 1.1     88 ± 0.3     84 ± 0.8     82 ± 1.5     80 ± 1.5                        
  Older Vit C    97 ± 0.3    93 ± 0.6     88 ± 0.8     86 ± 0.8     84 ± 0.9     81 ± 1.3                        
  EtCO2 (mmHg)                                                                                                   
  Young NSS      42 ± 1.6    42 ± 1.2     40 ± 1.5     41 ± 1.8     40 ± 1.8     40 ± 1.5     0.362    \<0.001   0.003
  Older NSS      35 ± 1.4    34 ± 1.5     34 ± 1.4     34 ± 1.5     33 ± 1.1     33 ± 1.1                        
  Young Vit C    41 ± 1.8    41 ± 1.1     41 ± 1.1     41 ± 1.0     40 ± 0.6     39 ± 0.9                        
  Older Vit C    34 ± 1.2    33 ± 1.3     33 ± 1.1     32 ± 1.1     32 ± 1.1     32 ± 1.2                        
  MV (L/min)                                                                                                     
  Young NSS      8.7 ± 0.9   11.3 ± 1.2   11.9 ± 1.2   10.2 ± 0.8   11.8 ± 1.7   11.4 ± 1.6   0.626    \<0.001   0.998
  Older NSS      9.9 ± 0.8   10.8 ± 0.9   10.3 ± 1.0   10.2 ± 0.7   12.1 ± 0.6   11.5 ± 0.6                      
  Young Vit C    9.9 ± 1.1   11.3 ± 0.7   11.3 ± 1.6   11.1 ± 1.8   11.7 ± 0.7   11.4 ± 0.9                      
  Older Vit C    9.3 ± 0.7   11.3 ± 0.8   11.0 ± 0.8   11.5 ± 1.0   11.0 ± 0.6   11.7 ± 0.5                      

In Experiment 2, eight older men and five young men were exposed to 5 min of continuously breathing 10% oxygen (hypoxia) while being infused both normal saline solution (NSS) and ascorbic acid (Vit C). Ascorbic acid had no significant effect on any of the measured variables.

In response to 5 min of breathing 21% oxygen (i.e., room air), there were no main effects for infusion or time ([Table 3](#tbl03){ref-type="table"}). However, the older men had higher MAP, lower FBF and lower EtCO2 compared to young men at all time points.

###### 

Physiologic responses to normoxia (21% oxygen) in Experiment 2.

                 Base         1 min        2 min        3 min       4 min        5 min       Infuse   Time    Age
  -------------- ------------ ------------ ------------ ----------- ------------ ----------- -------- ------- -------
  HR (bpm)                                                                                                    
  Young NSS      57 ± 3       57 ± 4       56 ± 4       56 ± 4      56 ± 5       56 ± 5      0.547    0.334   0.920
  Older NSS      55 ± 3       54 ± 2       56 ± 3       54 ± 3      55 ± 3       59 ± 3                       
  Young Vit C    54 ± 4       55 ± 4       56 ± 3       55 ± 3      53 ± 3       54 ± 3                       
  Older Vit C    56 ± 3       55 ± 2       54 ± 2       55 ± 2      57 ± 2       57 ± 2                       
  MAP (mmHg)                                                                                                  
  Young NSS      79 ± 6       80 ± 6       80 ± 6       81 ± 6      80 ± 7       80 ± 7      0.239    0.129   0.038
  Older NSS      91 ± 2       82 ± 3       91 ± 3       94 ± 3      94 ± 3       91 ± 3                       
  Young Vit C    79 ± 6       75 ± 7       77 ± 6       82 ± 7      77 ± 6       78 ± 7                       
  Older Vit C    88 ± 4       88 ± 4       88 ± 4       89 ± 4      91 ± 4       94 ± 1                       
  FBF (mL/min)                                                                                                
  Young NSS      39 ± 5       40 ± 7       38 ± 6       39 ± 7      37 ± 6       36 ± 2      0.35     0.136   0.002
  Older NSS      20 ± 3       16 ± 2       16 ± 2       15 ± 2      16 ± 2       20 ± 3                       
  Young Vit C    36 ± 4       41 ± 4       41 ± 3       38 ± 3      42 ± 3       39 ± 5                       
  Older Vit C    25 ± 4       21 ± 4       24 ± 4       21 ± 4      23 ± 4       23 ± 4                       
  CVC (au)                                                                                                    
  Young NSS      100 ± 0      109 ± 8      100 ± 3      104 ± 3     107 ± 7      109 ± 7     0.848    0.121   0.364
  Older NSS      100 ± 0      105 ± 4      96 ± 4       94 ± 7      99 ± 6       105 ± 6                      
  Young Vit C    100 ± 0      109 ± 5      103 ± 8      91 ± 4      111 ± 7      110 ± 8                      
  Older Vit C    100 ± 0      100 ± 5      99 ± 3       98 ± 2      101 ± 6      96 ± 6                       
  SaO2 (%)                                                                                                    
  Young NSS      98 ± 0.1     98 ± 0.1     98 ± 0.3     98 ± 0.3    98 ± 0.1     98 ± 0.3    0.368    0.111   0.07
  Older NSS      97 ± 0.4     98 ± 0.4     97 ± 0.4     97 ± 0.3    97 ± 0.3     98 ± 0.3                     
  Young Vit C    98 ± 0.3     98 ± 0.3     98 ± 0.5     97 ± 0.5    98 ± 0.5     98 ± 0.3                     
  Older Vit C    97 ± 0.2     97 ± 0.3     97 ± 0.2     97 ± 0.1    97 ± 0.2     97 ± 0.2                     
  EtCO2 (mmHg)                                                                                                
  Young NSS      43 ± 0.6     43 ± 1.1     43 ± 0.3     43 ± 0.4    43 ± 0.5     44 ± 0.5    0.52     0.007   0.002
  Older NSS      36 ± 1.4     36 ± 1.4     36 ± 1.4     36 ± 1.5    37 ± 1.6     37 ± 1.5                     
  Young Vit C    42 ± 0.8     41 ± 0.4     41 ± 0.3     44 ± 0.3    43 ± 0.8     42 ± 0.8                     
  Older Vit C    35 ± 0.8     35 ± 1.0     36 ± 1.0     36 ± 1.0    36 ± 1.1     37 ± 1.3                     
  MV (L/min)                                                                                                  
  Young NSS      8.8 ± 0.8    9.2 ± 0.4    9.6 ± 0.5    9.1 ± 0.4   9.3 ± 0.8    8.7 ± 0.9   0.881    0.683   0.689
  Older NSS      9.0 ± 0.6    8.7 ± 0.6    9.2 ± 0.6    8.5 ± 0.7   9.4 ± 1.0    8.9 ± 0.5                    
  Young Vit C    10.1 ± 0.7   10.2 ± 1.0   10.7 ± 0.6   9.8 ± 0.9   9.5 ± 0.7    9.3 ± 0.7                    
  Older Vit C    10.2 ± 0.9   9.2 ± 0.8    10.2 ± 0.9   9.3 ± 1.0   10.2 ± 0.7   9.1 ± 0.6                    

In Experiment 2, eight older men and five young men were exposed to 5 min of continuously breathing 21% oxygen (normoxia or room air) while being infused both normal saline solution (NSS) and ascorbic acid (Vit C). Ascorbic acid had no significant effect on any of the measured variables.

Discussion
==========

The purpose of this study was to determine the effect of aging on FVC and CVC responses to hypoxia and whether acute systemic infusion of ascorbic acid could modify these responses in older men. Consistent with our hypothesis, older men had an attenuated FVC response compared to young men when exposed to 5 min of hypoxia but CVC responses were comparable between groups. To our knowledge, this is the first evidence that hypoxia‐induced vasodilation is different between skin and muscle. The data from Experiment 2 do not support our original hypothesis that ascorbic acid would enhance hypoxia‐induced vasodilation in older men. These findings advance our basic understanding of how aging influences vascular responses to reduced blood oxygen levels and suggest that in healthy humans hypoxia‐induced vasodilation is not restrained by reactive oxygen species.

Exposure to hypoxia leads to a reduction in SaO2 and activation of the arterial (peripheral) chemoreflex which then stimulates ventilation and raises sympathetic outflow to skeletal muscle and the heart (Halliwill [@b16]). The current data are consistent with previous studies that demonstrated a blunted tachycardia in the older subjects in response to short‐duration hypoxia (Kronenberg and Drage [@b30]; Davy et al. [@b8]; Lhuissier et al. [@b35]). As expected, MAP was higher in the older men at all time points but was unaffected by 5 min of hypoxia. Respiratory responses were also not significantly influenced by age or ascorbic acid. Importantly, we demonstrated that FBF and FVC responses to hypoxia were attenuated in the older men. These findings are consistent with prior studies by Kirby et al. ([@b27]) and Kravec et al. ([@b29]). However, the current data are contrary to recent work by Casey et al. ([@b5]) and Limberg et al. ([@b36]); these two studies enrolled both men and women. Some potential reasons for the impaired FBF and FVC in older men include (1) enhanced sympathetic vasoconstrictor responses to hypoxia in the older men, (2) attenuated beta‐2 adrenergic vasodilation in the older men, (3) attenuated nitric oxide production in the older men (either due to aging per se or due to the attenuated HR response and resultant reduced shear stress release of nitric oxide), (4) alterations in other metabolites that respond to hypoxia in older men, and (5) augmented oxidative stress in the older men. These five reasons are discussed below.

First, aging is associated with increased SNS activity (Sundlof and Wallin [@b59]; Narkiewicz et al. [@b47]). However, changes in MSNA in response to acute hypoxia do not appear to be enhanced in older men (Davy et al. [@b8]). Richards et al. ([@b51]) recently demonstrated elevated alpha‐adrenergic vasoconstriction in response to hypoxia in older men but they suggested that several factors are likely responsible for an impaired vasodilatory response with aging. Second, Richards et al. ([@b51]) found that beta‐adrenergic vasodilation was attenuated in the aging population in response to hypoxia. Several studies have shown that up to 50% of hypoxia‐induced vasodilation is mediated by beta‐adrenergic receptors (Blauw et al. [@b1]; Weisbrod et al. [@b63]; Wilkins et al. [@b64]) and beta‐adrenergic receptors clearly become less responsive to agonists with age (Xiao and Lakatta [@b67]). Third, it has been demonstrated that nitric oxide (NO) signaling is a major contributor to the compensatory vasodilation at rest (Casey et al. [@b4]) and also that it is blunted in older individuals under hypoxic conditions (Casey et al. [@b5]). Indeed, blockade of NO production with L‐NMMA decreases the hypoxic forearm vasodilatory response in young adults (Blitzer et al. [@b2]; Casey et al. [@b4]). This indicates that hypoxic vasodilation requires functionally intact endothelium and subsequent NO release. Casey et al. ([@b5]) showed blunted NO signaling in older adults when compared to younger adults during hypoxic exercise while others have shown blunted NO responses to acetylcholine (Taddei et al. [@b61]) and flow‐ mediated dilation (Heiss et al. [@b17]) between these groups. Fourth, several other local vasodilatory signaling factors could play a significant role in hypoxia‐induced vasodilation including adenosine (Carlsson et al. [@b3]; Leuenberger et al. [@b33]), prostaglandins (Carlsson et al. [@b3]; Engelke et al. [@b10]), release of ATP from red blood cells (Kirby et al. [@b27]) and local myogenic factors (Carlsson et al. [@b3]; Schubert and Mulvany [@b55]; Koller and Bagi [@b28]); however, limited data exists on the role of these mechanisms on hypoxia‐induced vasodilation with aging.

Fifth, it is clear that aging is associated with heightened oxidative stress and impaired antioxidant defense (Sohal and Weindruch [@b57]). Physiological studies have demonstrated that ascorbic acid can acutely modify vascular responses in groups of people with elevated oxidative stress. Indeed, Taddei et al. ([@b61]) showed that intra‐arterial ascorbic acid infusion increased vasodilation in response to acetylcholine in older subjects and Holowatz et al. ([@b20]) demonstrated that acute intradermal ascorbate increased cutaneous vasodilation in the aged skin in response to whole body heating. We recently demonstrated that ascorbic acid (identical dose as in the current study) blocks the forearm vasoconstrictor response to 100% oxygen (i.e., an acute pro‐oxidant) and also normalizes exercise blood pressure in patients with peripheral arterial disease (i.e., a chronic condition characterized by high levels of systemic oxidative stress) (Muller et al. [@b42], [@b43]). Additionally, Eskurza et al. ([@b11]) demonstrated that intravenous ascorbic acid enhanced flow‐mediated forearm vasodilation in older men. Based on these previous studies and the fact that part of age‐related impairments in hypoxia‐induced vasodilation is endothelium dependent (Blitzer et al. [@b2]; Casey et al. [@b4]), we reasoned that ascorbic acid would enhance hypoxia‐induced vasodilation in the older men. Nevertheless, the current data (Experiment 2) suggest that oxidative stress does not play a significant role in hypoxia‐induced vasodilation because high‐ dose ascorbic (raising serum levels 10--20 fold above baseline) acid had no effect on vasodilator responses in young or older men. Our findings are consistent with a recent study that found no effect of intra‐arterial ascorbic acid on hypoxia‐induced vasodilation in heart failure (Nazare Nunes Alves et al. [@b48]). Taken together, the regulation of skeletal muscle blood flow during hypoxia involves these five factors listed above and there is considerable redundancy such that the alteration of one pathway due to aging may influence other pathways.

To our knowledge, no prior study has evaluated how hypoxia influences CVC in older adults. Our data, while not significant between groups, contribute importantly to the literature because previous work has found age impairments in the regulation of skin blood flow in response to heat (Kenney et al. [@b25]; Minson et al. [@b38]) and cold stress (Kenney and Armstrong [@b24]). Moreover, our CVC data suggest that age impairments in hypoxia‐induced vasodilation are present with regard to muscle blood flow but not skin blood flow. We speculate that cutaneous vasodilation in response to hypoxia is not simply a secondary effect of increased whole limb blood flow.

Experimental considerations
---------------------------

There are five main issues we would like to point out that may affect the interpretation of these data. First, we conducted acute studies and since aging is a chronic process, it is possible that the impairments in vascular function cannot be acutely altered (e.g., products of oxidative stress may chronically alter carotid body chemosensitive afferents or efferent nerve activity). Second, the forearm receives a relatively small percentage of cardiac output and we may have been able to detect larger effects had we measured the femoral artery instead of the brachial arterial or used a longer duration of hypoxia. Third, although blood sampling did detect commonly observed age‐related differences in LDL cholesterol (Miller [@b37]), hs‐CRP (Woloshin and Schwartz [@b66]), and fibrinogen (Laharrague et al. [@b31]; Hager et al. [@b15]; Fu and Nair [@b13]) the older men in our study were quite healthy. Therefore, it is possible that people with more cardiovascular risk factors would show different responses than these older, healthy men (i.e. oxidative stress may play a bigger role in older, less healthy men). To support this theory, the young men in this experiment, with presumably healthy endothelial function showed no change to ascorbic acid as well. Fourth, maximal skin blood flow is reduced in older adults (Holowatz et al. [@b22]) and since we did not perform local heating, the CVC data presented in this study are not normalized to each individual\'s maximum skin blood flow (i.e., the older adults were operating at a higher relative percent of maximum). Fifth, it is possible that ascorbic acid did not affect the ROS species that are important in the age‐impairment in skeletal muscle hypoxia‐induced vasodilation.

Clinical implications
---------------------

Attenuated vasodilator responses in the forearm may translate to attenuated responses in other vascular beds. For instance, there may be an increased risk of myocardial injury upon exposure to acute hypoxia in older adults. Furthermore, patients with chronic obstructive pulmonary disease and obstructive sleep apnea (i.e., chronic intermittent hypoxia) tend to be older so it is likely that the cardiovascular complications of these diseases are also influenced by the aging process. However, our findings question whether age‐related impairments in muscle (or coronary) blood flow can be modified by acute administration of ascorbic acid. Moreover, these data highlight that skin and muscle blood flow responses to hypoxia are differentially affected by the aging process.

Conclusions
===========

Healthy older men have a blunted hypoxia‐induced vasodilation in forearm skeletal muscle compared to young men but forearm skin blood flow responses were comparable between groups. The age‐related impairment in hypoxia‐induced vasodilation was not altered by systemic infusion of ascorbic acid which suggests that oxidative stress does not play a mechanistic role in this process. Future studies may enroll older patients with cardiopulmonary disease to further investigate hypoxia‐induced vasodilation in different vascular beds.
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